ArticleJournal of gastrointestinal oncology2025
Expression of PDZ domain-containing proteins is correlated with prognosis and immune infiltration in hepatocellular carcinoma.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC)-a predominant type of primary liver cancer-poses a significant global health threat with high incidence and mortality rates. Despite advances in treatment modalities, including surgery, chemotherapy, and immunotherapy, HCC exhibits high relapse rates and low long-term survival, necessitating the identification of novel prognostic markers and treatment targets. This study aims to develop a prognostic model centered on the PDZ domain by identifying key PDZ proteins associated with HCC through bioinformatics analysis of large-scale public datasets, in order to improve prognosis prediction and inform therapeutic strategies. Methods: Differentially expressed PDZ proteins (DEPs) in HCC were identified through RNA sequencing (RNA-seq) analysis from The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC), and Gene Expression Omnibus (GEO) databases. Cox regression and random survival forest (RSF) modeling were employed to construct a prognostic model and evaluate the prognostic potential of DEPs. Subsequently, the correlation of DEP-related risk scores with immune cell infiltration and genetic variations was analyzed separately. Quantitative polymerase chain reaction (qPCR) was conducted to validate the expression of key DEPs in HCC tissues. Results: A prognostic model for HCC constructed using nine key DEPs demonstrated reliable predictive performance across 1-, 3-, and 5-year survival rates. DEP-related risk scores were significantly associated with immune cell infiltration, with high-risk groups exhibiting an increase in pro-tumor immune cells and a decrease in anti-tumor immune cells. Genetic variations, including single nucleotide polymorphisms (SNPs) and copy number variations (CNVs), also differed between high- and low-risk groups. qPCR validation confirmed that the expression of SNX27, DLG5, PARD3, and RHPN1 was significantly upregulated in HCC tissues. Conclusions: PDZ proteins may serve as prognostic markers and therapeutic targets in HCC. DEP-related risk scores offer insights into immune infiltration patterns and treatment responsiveness, providing a foundation for future HCC research and development of precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.